Table 2.
Baseline characteristics of included patients.
| Trials | Region | Treatment | Populations | Age (SD) | Female Sex (%) | BMI (SD) | Age at onset (SD) | MMD (SD) | MSMD (SD) | Failed Previous Migraine-Preventive Medications |
|---|---|---|---|---|---|---|---|---|---|---|
| Sakai 2019 | Japan | Erenumab 70 mg | 135 | 44(NA) | 115(85.2%) | 21.6(3.5) | NA | 7.8(2.3) | 5.4(2.9) | 43 |
| Erenumab 140 mg | 137 | 45(NA) | 112(81.8%) | 22(3.5) | NA | 8.1(2.4) | 5.9(2.9) | 54 | ||
| Placebo | 136 | 45(NA) | 118(86.8%) | 22.1(3.5) | NA | 7.7(2.3) | 5.6(2.5) | 44 | ||
| Dodick 2018 | North America and Europe | Erenumab 70 mg | 286 | 42(11) | 245(85.7%) | 27.4(6.3) | 21(10) | 8.1(2.7) | 3.7(3.6) | 117 |
| Placebo | 291 | 42(12) | 247(84.9%) | 27.4(6.1) | 22(11) | 8.4(2.6) | 3.4(3.6) | 115 | ||
| Goadsby 2017 | North America, Europe and Turkey | Erenumab 70 mg | 317 | 41.1(11.3) | 268(84.5%) | 27.3(5.9) | 21.4(11) | 8.3(2.5) | 3.2(3.4) | 127 |
| Erenumab 140 mg | 319 | 40.4(11.1) | 272(85.3%) | 27(6.2) | 20.7(9.9) | 8.3(2.5) | 3.4(3.5) | 116 | ||
| Placebo | 319 | 41.3(11.2) | 274(85.9%) | 27.1(6.3) | 21.2(10.2) | 8.2(2.5) | 3.4(3.4) | 127 | ||
| Sun 2016 | North America and Europe | Erenumab 70 mg | 107 | 42.6(9.9) | 82(76.6%) | 25.8(4.9) | 21.7(11.7) | 8.6(2.5) | 4.3(3.5) | 34 |
| Placebo | 160 | 41.4(10) | 132(82.5%) | 25.9(4.9) | 20.7(11.5) | 8.8(2.7) | 4.5(3.9) | 60 | ||
| Reuter 2018 | Europe and Australia | Erenumab 140 mg | 121 | 44.6(10.5) | 97(80.2) | 25(4.2) | NA | 9.2(2.6) | 4.8(2.9) | 121 |
| Placebo | 125 | 44.2(10.6) | 103(82.4%) | 24.9(5.1) | NA | 9.3(2.7) | 4.4(2.8) | 125 |
NA=not applicable; BMI=Body Mass Index; MMD=Monthly Migraine Days; MSMD=Monthly Acute Migraine-Specific Medication Treatment Days.